The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia.
Epilepsia Open
; 7(3): 488-495, 2022 09.
Article
in En
| MEDLINE
| ID: mdl-34653311
ABSTRACT
Focal cortical dysplasia (FCD) is one of the most common malformations causing refractory epilepsy. Dysregulation of glutamatergic systems plays a critical role in the hyperexcitability of dysplastic neurons in FCD lesions. The pharmacoresistant nature of epilepsy associated with FCD may be due to a lack of well-tolerated and precise antiepileptic drugs that can target glutamate receptors. Here, for the first time in human FCD brain slices, we show that the established, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, perampanel has potent antiepileptic action. Moreover, we demonstrate that this effect is due to a reduction in burst firing behavior in human FCD microcircuits. These data support a potential role for the treatment of refractory epilepsy associated with FCD in human patients.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Epilepsy
/
Malformations of Cortical Development
/
Drug Resistant Epilepsy
Limits:
Humans
Language:
En
Journal:
Epilepsia Open
Year:
2022
Document type:
Article
Affiliation country:
Reino Unido